$XBI $127 +2%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$VIR +13% GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients. source
$ALT +9% Altimmune Demonstrates Strong Neutralization Of South African Variant In Preclinical Study Of Intranasal AdCOVID™. source
Pipeline Updates
$LEGN +5% U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma. source
$MYOV +5% Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids. source
$GLYC +5% GlycoMimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation. source
$APVO +1% Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia. source
$PTCT +1% PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia. source
$RVNC +6% Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection. source
$PCRX -5% PACIRA BIOSCIENCES ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 STRIDE STUDY EVALUATING EXPAREL AS A LOWER EXTREMITY NERVE BLOCK. source
$VTGN -9% VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder. source
$KMPH -1% KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status. source
$CFRX +5% CONTRAFECT ANNOUNCES MULTIPLE PUBLICATIONS ON EXEBACASE, INCLUDING FIRST MANUSCRIPT ON LOCAL ADMINISTRATION OF LYSIN FOR POTENTIAL TREATMENT OF PROSTHETIC JOINT INFECTIONS. source
$ADCT +4% ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology. source
$CCCC +8% C4 THERAPEUTICS TO ADVANCE CFT8919, A SELECTIVE DEGRADER OF EGFR L858R, INTO IND-ENABLING STUDIES. source
$EBS +1% Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate. source
Posted by DV